` 6LUA (Novan Inc) vs DAX Index Comparison - Alpha Spread

6LUA
vs
DAX Index

Over the past 12 months, 6LUA has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's 27% growth.

Stocks Performance
6LUA vs DAX Index

Loading
6LUA
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
6LUA vs DAX Index

Loading
6LUA
DAX Index
Difference
www.alphaspread.com

Performance By Year
6LUA vs DAX Index

Loading
6LUA
DAX Index
Add Stock

Competitors Performance
Novan Inc vs Peers

DAX Index
6LUA
LLY
JNJ
NOVO B
ROG
Add Stock

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available
Back to Top